Section 232 MedTech Investigation – 2026 Outlook

Section 232 MedTech investigation is in flight. Scope and rate determination remain pending; summer 2026 earliest action. Affected industries: medical devices, diagnostics, surgical instruments, specific medical adjacencies. For SMB MedTech firms, scenario modeling under several plausible scope structures is recommended.

This guide covers Section 232 MedTech Investigation – 2026 Outlook. Section 232 of the Trade Expansion Act of 1962 authorizes tariffs on imports based on national security findings.

For SMB importers, Section 232 exposure depends on HS classification, country of origin, and current effective rate (which has varied through administrative determinations).

Investigation status

Commerce Department investigation in progress. Specific scope and rate will be determined in the proclamation when issued.

Likely scope

Medical devices, diagnostics, surgical instruments are likely candidates. Drug-device combinations sit at boundary with the pharma probe.

Industries affected

Twin Cities MedTech cluster (Medtronic, Boston Scientific, 3M), Boston biotech, Bay Area medical-device startups, Irish MedTech (Coloplast, William Demant).

Preparedness for SMB MedTech

HTS classification review, supplier shift feasibility, USMCA qualification on Mexican production, scenario modeling.

Frequently asked questions

Does Section 232 still apply in 2026?

Yes. Section 232 has no statutory expiration. Steel and aluminum since 2018; copper added 2026; pharma effective July 31, 2026. MedTech and semiconductor investigations in flight.

Does Section 232 stack with Section 122?

Generally no. Section 232-covered goods pay Section 232 in lieu of Section 122. Edge cases exist where finished goods contain Section 232 inputs but are not themselves covered.

Can I file for a Section 232 exclusion?

Specific exclusion processes have applied historically (especially for steel and aluminum). Current exclusion windows vary; we track active processes.

How does Section 232 derivative scope work?

Derivatives expansion brings downstream products into scope at the HTS subheading level. Component-level analysis identifies actual coverage for finished goods.

How do you help with Section 232 work?

Scope analysis, supplier shift modeling, product petition filings, and exclusion request support. Engagements typically $5,000-$15,000 fixed-fee.